Aberdeen Group plc Lowers Stock Holdings in Corcept Therapeutics Incorporated $CORT

Aberdeen Group plc lessened its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 5.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 245,093 shares of the biotechnology company’s stock after selling 13,984 shares during the quarter. Aberdeen Group plc owned about 0.23% of Corcept Therapeutics worth $8,529,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CORT. AQR Capital Management LLC increased its stake in Corcept Therapeutics by 546.9% during the 3rd quarter. AQR Capital Management LLC now owns 1,507,209 shares of the biotechnology company’s stock worth $125,264,000 after buying an additional 1,274,215 shares during the period. JPMorgan Chase & Co. increased its position in shares of Corcept Therapeutics by 223.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 849,864 shares of the biotechnology company’s stock worth $70,632,000 after purchasing an additional 587,053 shares during the last quarter. UBS Group AG increased its position in shares of Corcept Therapeutics by 413.8% in the 3rd quarter. UBS Group AG now owns 549,938 shares of the biotechnology company’s stock worth $45,705,000 after purchasing an additional 442,898 shares during the last quarter. Pacer Advisors Inc. increased its position in shares of Corcept Therapeutics by 6,796.7% in the 3rd quarter. Pacer Advisors Inc. now owns 390,559 shares of the biotechnology company’s stock worth $32,459,000 after purchasing an additional 384,896 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Corcept Therapeutics by 111.8% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 507,967 shares of the biotechnology company’s stock worth $19,404,000 after purchasing an additional 268,155 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $41.87 on Thursday. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. Corcept Therapeutics Incorporated has a fifty-two week low of $28.66 and a fifty-two week high of $91.00. The firm has a 50-day simple moving average of $37.54 and a 200 day simple moving average of $58.83. The company has a market cap of $4.45 billion, a PE ratio of 51.06 and a beta of 0.25.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). The business had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. Corcept Therapeutics’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the company earned $0.26 EPS. On average, sell-side analysts anticipate that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Negative Sentiment: Multiple securities class-action filings and firm solicitations allege misstatements related to FDA data concerns and investor losses, and several firms are reminding shareholders of an April 21, 2026 lead‑plaintiff deadline. This amplifies potential litigation risk and headline pressure on CORT. Corcept (CORT) Class Action Alleges Misstatements on FDA Data Concerns – Hagens Berman
• Negative Sentiment: Numerous plaintiff firms (Rosen, Kahn Swick & Foti, Pomerantz, Bronstein Gewirtz & Grossman, Kaplan Fox, Rosen, Gross, others) are actively soliciting Corcept investors and urging lead‑plaintiff filings for the same class period — increasing the likelihood of consolidated litigation and associated distraction/costs. ROSEN deadline alert
• Negative Sentiment: Insider sale: director William Guyer sold 20,000 shares at ~$40.97 under a pre‑arranged Rule 10b5‑1 plan (proceeds ~$819K), leaving him with ~2,231 shares — an ~90% decline in his holding. Large insider sales can be viewed negatively even if pre‑planned. SEC filing: Guyer sale

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on CORT shares. Weiss Ratings reissued a “hold (c)” rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. Zacks Research downgraded shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. HC Wainwright dropped their target price on shares of Corcept Therapeutics from $67.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, March 25th. Truist Financial raised shares of Corcept Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Canaccord Genuity Group boosted their target price on shares of Corcept Therapeutics from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $77.67.

Insider Buying and Selling at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $40.97, for a total transaction of $819,400.00. Following the completion of the transaction, the insider directly owned 2,231 shares of the company’s stock, valued at $91,404.07. The trade was a 89.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joseph K. Belanoff sold 26,198 shares of the business’s stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $50.07, for a total transaction of $1,311,733.86. Following the transaction, the chief executive officer directly owned 2,918,326 shares of the company’s stock, valued at $146,120,582.82. The trade was a 0.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 86,198 shares of company stock valued at $3,668,569 in the last ninety days. Company insiders own 20.80% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.